biotech

GSK Acquires Tesaro in a USD 5.1 Billion Deal

GSK Acquires Tesaro in a USD 5.1 Billion Deal

GlaxoSmithKline (NYSE: GSK) announced on Monday that it will acquire Tesaro (NASDAQ: TSRO) for USD 5.1 Billion.This marks the first big acquisition since Hal Barron, a pharma veteran and experienced scientist took on the role of chief scientific off..

Biocept and Alliance Global FZ form agreement to market and distribute liquid biopsy testing in Middle East, Southeast Asia, and Africa

Biocept and Alliance Global FZ form agreement to market and distribute liquid biopsy testing in Middle East, Southeast Asia, and Africa

Biocept Inc. (NASDAQ: BIOC) announced today that it has entered a provider agreement with Alliance Global FZ, LLC to market and distribute Biocept’s Target Selector liquid biopsy tests in the United Arab Emirates, and select countries in ..

Biogen Reports Positive Results on Alzheimer's Trial, Shares Soar

Biogen Reports Positive Results on Alzheimer's Trial, Shares Soar

Biogen Inc. (NASDAQ: BIIB) announced today that the outcome of its large clinical trial consisting of 856 patients regarding an Alzheimer’s drug produced positive results. Together with its Japanese partner, Eisai Co., the experimental dr..

Gilead Shares Fall After Hepatitis C treatment Sales Plunge

Gilead Shares Fall After Hepatitis C treatment Sales Plunge

Gilead Sciences Inc. (NASDAQ: GILD) reported its first quarter financial results after market close on Tuesday and missed analysts estimates. Shares fell by 7 percent after the opening bell on Wednesday.For the first quarter, Gilead reported revenue..

Bayer to Get Approval from Justice Department to Acquire Monsanto

Bayer to Get Approval from Justice Department to Acquire Monsanto

According to the person familiar with the matter, Bayer AG, the German drugs and pesticides group, is to get approval from the U.S. Justice Department to acquire Monsanto Company (NYSE: MON) for $62.5 billion.Shares of Monsanto rose 6.5% to $125.47 ..

AbbVie Shares Up on Stronger than Expected Q4 Beat

AbbVie Shares Up on Stronger than Expected Q4 Beat

AbbVie Inc. (NYSE: ABBV) reported its fourth quarter financial results for fiscal year 2017. The pharmaceutical company reported better than expected earnings sending shares 13.5 percent before market close on Friday.For the fourth quarter, AbbVie r..